Trial completion shift to 2023 is unfortunate.
On the positive, company is actively working with different markets and provided tangible updates for Japan, Canada, US, India and China. Data from Monash trial so far appears to exceed clinical expectations.
Ann: FELIX System commercialisation, regulatory plan and trial, page-5
-
- There are more pages in this discussion • 24 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MEM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $9.679M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 5037555 | 0.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.8¢ | 1058594 | 7 |
View Market Depth
| Last trade - 12.03pm 01/07/2024 (20 minute delay) ? |
| MEM (ASX) Chart |
Day chart unavailable